source
- ARPA-H selects UpDoc, Tempus AI and Atman Health for new AI heart-disease programARPA-H announced a new initiative called ADVOCATE that will bring together three companies to develop AI-driven tools for managing heart disease. The selected firms - UpDoc, Tempus AI, and Atman H…
- Novartis' del-desiran misses primary goal in late-stage myotonic dystrophy trialNovartis announced that its experimental RNA drug del-desiran did not achieve the primary endpoint in a late-stage study of myotonic dystrophy type 1, a rare muscle‑weakening disease. The trial me…